Plexium debuts with $28M, aims to induce protein degradation by searching all possibilities

Plexium has launched with a $28 million series A and a platform that connects its DNA-encoded library with high throughput cell-based screening, allowing the protein degradation company to sort through millions of compounds for those that send E3 ligases to therapeutic targets.

DCVC Bio and The Column Group led the round, with participation from M Ventures, Charles River Ventures and Neotribe Ventures...